Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2009 Jul;68(1):106-15.
doi: 10.1111/j.1365-2125.2009.03410.x.

Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada)

Nadia Barozzi  1 , Ingrid Sketris, Charmaine Cooke, Susan Tett
Affiliations
Comparative Study

Comparison of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors use in Australia and Nova Scotia (Canada)

Nadia Barozzi et al. Br J Clin Pharmacol. 2009 Jul.

Abstract

Aims: Cyclooxygenase-2 (COX-2) inhibitors were marketed aggressively and their rapid uptake caused safety concerns and budgetary challenges in Canada and Australia. The objectives of this study were to compare and contrast COX-2 inhibitors and nonselective nonsteroidal anti-inflammatory drug (ns-NSAID) use in Nova Scotia (Canada) and Australia and to identify lessons learned from the two jurisdictions.

Methods: Ns-NSAID and COX-2 inhibitor Australian prescription data (concession beneficiaries) were downloaded from the Medicare Australia website (2001-2006). Similar Pharmacare data were obtained for Nova Scotia (seniors and those receiving Community services). Defined daily doses per 1000 beneficiaries day(-1) were calculated. COX-2 inhibitors/all NSAIDs ratios were calculated for Australia and Nova Scotia. Ns-NSAIDs were divided into low, moderate and high risk for gastrointestinal side-effects and the proportions of use in each group were determined. Which drugs accounted for 90% of use was also calculated.

Results: Overall NSAID use was different in Australia and Nova Scotia. However, ns-NSAID use was similar. COX-2 inhibitor dispensing was higher in Australia. The percentage of COX-2 inhibitor prescriptions over the total NSAID use was different in the two countries. High-risk NSAID use was much higher in Australia. Low-risk NSAID prescribing increased in Nova Scotia over time. The low-risk/high-risk ratio was constant throughout over the period in Australia and increased in Nova Scotia.

Conclusions: There are significant differences in Australia and Nova Scotia in use of NSAIDs, mainly due to COX-2 prescribing. Nova Scotia has a higher proportion of low-risk NSAID use. Interventions to provide physicians with information on relative benefits and risks of prescribing specific NSAIDs are needed, including determining their impact.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall nonsteroidal anti-inflammatory drug (NSAID), nonselective (ns)-NSAID, cyclooxygenase-2 (COX-2) inhibitor and meloxicam use in Australia and Nova Scotia between 2001 and 2006. COX-2 inhibitors NS (—○—); COX-2 inhibitors AUS (formula image); ns-NSAIDs NS (—⋆—); ns-NSAIDs AUS (—⋆—); meloxicam NS (—▵—); meloxicam AUS (—▴—); All NSAIDs NS (—□—); All NSAIDs AUS (formula image)
Figure 2
Figure 2
Nonsteroidal anti-inflammatory drug (NSAID) drug utilization 90% (DU90%) in Australia and Nova Scotia between 2001 and 2006
Figure 3
Figure 3
Nonselective nonsteroidal anti-inflammatory drug (ns-NSAID) utilization by risk for gastrointestinal (GI) side-effects (blocks, left axis) and low/high risk ratio (lines, right axis) in Australia and Nova Scotia between 2001 and 2006. others not classified (formula image); meloxicam (formula image); high risk (formula image); moderate risk (formula image); low risk (formula image); Low-risk / High-risk ratio (formula image)
See this image and copyright information in PMC

References

    1. Hawkins C, Hanks G. The gastoduodenal toxicity of nonsteroidal anti-inflammatory drugs. A review of the literature. J Pain Symptom Manage. 2000;20:140–51. - PubMed
    1. Jones R. Nonsteroidal anti-inflammatory drug prescribing: past, present, and future. Am J Med. 2001;110:4S–7S. - PubMed
    1. Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, Bell M, Hawker GA, Juby A, Vanner S, Sibley J. An evidence-based approach toprescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Can Med Assoc J. 1996;155:77–88. - PMC - PubMed
    1. Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. Intern Med J. 2006;36:308–19. - PubMed
    1. Kearney P, Baignent C, Godwin J, Halls H, Emerson J. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332:1302–8. - PMC - PubMed

Publication types

MeSH terms

Substances